TY - JOUR
T1 - GP IIb/IIIa inhibitors in coronary artery disease management
T2 - What the latest trials tell us
AU - Chew, D. P.
AU - Moliterno, D. J.
PY - 2001
Y1 - 2001
N2 - Recent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes.
AB - Recent clinical trials have refined our understanding of how the glycoprotein (GP) IIb/IIIa inhibitors should best be used. These trials examined whether there are clinical differences between agents, whether empiric use of GP IIb/IIIa inhibitors in acute coronary syndromes is justified, and whether these drugs might allow for early invasive management in acute coronary syndromes.
UR - http://www.scopus.com/inward/record.url?scp=0035666507&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035666507&partnerID=8YFLogxK
U2 - 10.3949/ccjm.68.12.1017
DO - 10.3949/ccjm.68.12.1017
M3 - Article
C2 - 11765119
AN - SCOPUS:0035666507
SN - 0891-1150
VL - 68
SP - 1017
EP - 1023
JO - Cleveland Clinic Journal of Medicine
JF - Cleveland Clinic Journal of Medicine
IS - 12
ER -